Sadou Lisa, Pilmis Benoît, Eid Rasha, Moenne Locoz Pierre, Lefèvre Sophie, Jauréguy Françoise, Rathouin Vanessa, Zahar Jean-Ralph, Foucault-Fruchard Laura
Unité de Prévention du Risque Infectieux, Department of Clinical Microbiology, AP-HP, Groupe Hospitalier Paris Seine Saint-Denis, 93000 Bobigny, France.
Equipe Mobile de Microbiologie Clinique, Hôpitaux Saint-Joseph et Marie-Lannelongue, 75014 Paris, France.
Life (Basel). 2025 Jul 4;15(7):1072. doi: 10.3390/life15071072.
Enterobacterales are among the most frequent causes of healthcare-associated infections and are increasingly affected by antimicrobial resistance. Antibiotic use disrupts the gut microbiota, facilitating colonization by multidrug-resistant organisms, including carbapenemase-producing Enterobacterales (CPE). While animal studies have suggested that certain antibiotic classes may increase the risk of CPE acquisition, clinical data identifying which classes are most implicated remain limited.
We conducted a single-center, retrospective case-control study (2021-2024) comparing antibiotic prescriptions in patients who acquired CPE with those in controls hospitalized in the same unit and during the same risk period but who did not acquire CPE. The objective of this study was to identify which antibiotic classes or pharmacological properties are associated with the acquisition of carbapenemase-producing Enterobacterales (CPE) in hospitalized patients.
During the study period, 35 cases and 70 controls were included. Most cases acquired NDM-type metalloenzymes. Before the risk period, 55 patients had received antibiotic therapy. Univariate analysis identified an association between CPE acquisition and the prescription of fluoroquinolones and antibiotics excreted in bile. During the risk period, only metronidazole prescription was significantly associated with CPE acquisition. Our study has several limitations, including the small sample size, the single-center retrospective design, and the lack of molecular typing (e.g., WGS) to confirm potential clonal transmission.
In this preliminary study, metronidazole use was associated with an increased risk of CPE acquisition during risk periods. However, these results should be interpreted cautiously and need to be confirmed in larger, multicenter studies. The high exposure of patients to multiple antibiotic classes highlights the importance of strict antibiotic stewardship policies in the current era of global CPE dissemination.
肠杆菌科细菌是医疗保健相关感染的最常见病因之一,且越来越多地受到抗菌药物耐药性的影响。抗生素的使用会破坏肠道微生物群,促进包括产碳青霉烯酶肠杆菌科细菌(CPE)在内的多重耐药菌的定植。虽然动物研究表明某些抗生素类别可能会增加获得CPE的风险,但确定哪些类别最相关的临床数据仍然有限。
我们进行了一项单中心回顾性病例对照研究(2021 - 2024年),比较获得CPE的患者与在同一病房、同一风险期住院但未获得CPE的对照患者的抗生素处方情况。本研究的目的是确定哪些抗生素类别或药理特性与住院患者获得产碳青霉烯酶肠杆菌科细菌(CPE)有关。
在研究期间,纳入了35例病例和70例对照。大多数病例获得了NDM型金属酶。在风险期之前,55名患者接受了抗生素治疗。单因素分析确定CPE的获得与氟喹诺酮类药物和经胆汁排泄的抗生素的处方之间存在关联。在风险期,只有甲硝唑的处方与CPE的获得显著相关。我们的研究有几个局限性,包括样本量小、单中心回顾性设计以及缺乏分子分型(如全基因组测序)来确认潜在的克隆传播。
在这项初步研究中,甲硝唑的使用与风险期获得CPE的风险增加有关。然而,这些结果应谨慎解释,需要在更大规模的多中心研究中得到证实。患者对多种抗生素类别的高暴露凸显了在当前全球CPE传播时代严格抗生素管理政策的重要性。